Filing Flows › Strive (ASST) › Q2 2026 › vs Q2 2025
Strive (ASST) Q2 2026 vs Q2 2025 (year over year)
Strive's revenue rose $1.4M (+95%) from $1.5M in Q2 2025 to $2.9M in Q2 2026. The biggest changes: Medical device revenues +$1.4M (—); Investment advisory fees +$24K (+2%); Other revenue +$18K (+78%).
Strive, Q2 2026: revenue $2.9M (+95% year over year), net loss $258M, operating cash flow −$8.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Investment advisory fees | $1.5M | $1.5M | $24K | +2% |
| Medical device revenues | $1.4M | $0 | $1.4M | — |
| Other revenue | $41K | $23K | $18K | +78% |
| Revenue | $2.9M | $1.5M | $1.4M | +95% |
| Other income, net | $646K | −$5.2M | $5.8M | — |
| Net loss | $258M | $8.9M | $249M | 29× |
| Costs & expenses | $261M | $10.4M | $251M | 25× |
| Operating costs | $261M | $5.2M | $256M | 50× |
| Sales & marketing | $79K | $102K | −$23K | -23% |
| General & admin | $6.4M | $1.5M | $5.0M | +343% |
| Other operating costs | $255M | $3.6M | $251M | 71× |
| Operating cash sources | $258M | $8.9M | $249M | 29× |
| Depreciation & amortization | $86K | $54K | $32K | +59% |
| Share-based compensation | $5.7M | $0 | $5.7M | — |
| Working capital & other | $243M | $4.4M | $239M | 55× |
| Cash used in operations | $8.4M | $4.4M | $4.0M | +90% |
| Net loss absorbed | $258M | $8.9M | $249M | 29× |
Questions
How much did Strive's revenue grow year over year in Q2 2026?
Strive's revenue rose $1.4M (+95%) from $1.5M in Q2 2025 to $2.9M in Q2 2026.
What drove Strive's revenue change in Q2 2026?
Medical device revenues +$1.4M (—); Investment advisory fees +$24K (+2%); Other revenue +$18K (+78%).